Acquisitions, Trial Study Results, Drug Trend Reports, Conference Call Schedules, and Product Launches - Analyst Notes on Mallinckrodt, Amgen, Express Scripts, CR Bard, and Jazz

NEW YORK, April 10, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Amgen Inc. (NASDAQ: AMGN), Express Scripts Inc. (NASDAQ: ESRX), CR Bard Inc. (NYSE: BCR), and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Mallinckrodt plc Analyst Notes 

On April 7, 2014, Mallinckrodt plc (Mallinckrodt) announced agreement to acquire Questcor Pharmaceuticals, Inc. (Questcor) for approximately $5.6 billion, in a move to boost its specialty pharmaceuticals portfolio and gain access to Questcor's high-growth H.P. Acthar Gel which generated sales of $761.3 million in 2013. The Board of Directors of both the Companies approved the transaction, which is expected to be completed in Q3 2014. As per the terms of the transaction, Mallinckrodt will pay cash and stock valued at $86.10 per share to Questcor, which represents a premium of around 27% over Questcor's close price as of April 4, 2014. Upon completion of the merger, Mallinckrodt shareholders will own approximately 50.5% and former Questcor shareholders will own approximately 49.5% of the combined entity's stock. Mallinckrodt, which also recently acquired Cadence Pharmaceuticals in February 2014, expects the transaction to be immediately accretive to its full-year 2014 adjusted diluted EPS, and significantly accretive to its full-year 2015 adjusted diluted EPS. The full analyst notes on Mallinckrodt plc are available to download free of charge at:

http://www.AnalystsReview.com/04102014/MNK/report.pdf

--

Amgen Inc. Analyst Notes 

On April 4, 2014, Amgen Inc. (Amgen) announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma. The Company informed that the OS analysis evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). As per the results, the primary end point of durable response rate was met (as previously reported), but the secondary endpoint of OS was not met, although there was a strong trend in favor of talimogene laherparepvec (p=0.051). "We remain encouraged that the study met its primary endpoint of achieving durable responses in patients with metastatic melanoma," said Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen. The full analyst notes on Amgen Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/AMGN/report.pdf

--

Express Scripts Inc. Analyst Notes 

On April 8, 2014, Express Scripts Holding Co. (Express Scripts), a U.S. based pharmacy benefit manager, stepped up its efforts to stop the skyrocketing prices of specialty drugs which now account for 28% of total spending on drugs in U.S., Bloomberg reported. The report stated that Express Scripts has criticized Gilead Sciences Inc. (Gilead) for pricing its new hepatitis C drug Sovaldi as high as $84,000 for a 12-week course of treatment, or $1,000 a day. The Company also plans to ask its clients, comprising national employers, health insurance plans and government agencies, to join a coalition that would stop drug companies from resorting to such practices which, it believes, will make pharmacy benefits unsustainable. Express Scripts' annual Drug Trend Report revealed that spending on specialty drugs increased 14% in 2013 and predicted it will leap another 63% by the end of 2016 based mainly on prices for new pills to treat the 2.7 million Americans with hepatitis C. The full analyst notes on Express Scripts Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/ESRX/report.pdf

--

CR Bard Inc. Analyst Notes 

On April 1, 2014, CR Bard Inc. (Bard) announced that it will release its Q1 2014 financial results on April 22, 2014, after the market close, followed by a conference call at 5:00 p.m. EDT, to discuss the results, and to provide financial guidance for Q2 2014. In the previous quarter (Q4 2013), the Company reported a 3.8% increase in net sales to $791.3 million. Net income was reported at $667.5 million, or $8.28 per diluted share. The full analyst notes on CR Bard Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/BCR/report.pdf

--

Jazz Pharmaceuticals plc Analyst Notes 

On March 31, 2014, Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) and its majority owned indirect subsidiary Gentium S.p.A. jointly announced the beginning of the European commercial launch of Defitelio® (Defibrotide), the first licensed product for the treatment of severe hepatic veno-occlusive disease (severe VOD or sVOD) in patients over one month of age undergoing haematopoietic stem cell transplantation (HSCT) therapy. The duos have launched Defitelio in Germany and Austria and expect to continue the launch in 27 additional European countries on a rolling basis during 2014 and 2015. According to the Companies, the efficacy of Defitelio to treat sVOD in HSCT patients is supported by data from a pivotal, multi-centre Phase 3 trial that evaluated Defitelio for the treatment of sVOD compared with a historical control group of patients who had received standard supportive care. The full analyst notes on Jazz Pharmaceuticals plc are available to download free of charge at:

http://www.AnalystsReview.com/04102014/JAZZ/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED